Beijing Tongyu Technology

Beijing Tongyu Biotechnology is a Chinese biotechnology company specializing in the development of next-generation RNA therapeutics, with a primary focus on circular RNA (circRNA) technology. Founded in 2021 by a team of experts in RNA biology, the company aims to overcome the limitations of linear mRNA, such as stability and expression duration, by leveraging the unique structural properties of circRNA. Their platform supports the development of vaccines and protein replacement therapies across various therapeutic areas, including infectious diseases and oncology. Tongyu Bio is currently in the pre-clinical stage, advancing its proprietary pipeline while establishing manufacturing capabilities for RNA-based medicines.